During the last session, Kura Oncology Inc (NASDAQ:KURA)’s traded shares were 1.15 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stock’s price was $21.98, reflecting an intraday loss of -3.72% or -$0.85. The 52-week high for the KURA share is $24.17, that puts it down -9.96 from that peak though still a striking 66.29% gain since the share price plummeted to a 52-week low of $7.41. The company’s market capitalization is $1.67B, and the average intraday trading volume over the past 10 days was 1.06 million shares, and the average trade volume was 1.52 million shares over the past three months.
Kura Oncology Inc (NASDAQ:KURA) trade information
Kura Oncology Inc (KURA) registered a -3.72% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.72% in intraday trading to $21.98, hitting a weekly high. The stock’s 5-day price performance is -1.26%, and it has moved by 12.78% in 30 days. Based on these gigs, the overall price performance for the year is 87.54%. The short interest in Kura Oncology Inc (NASDAQ:KURA) is 11.02 million shares and it means that shorts have 7.71 day(s) to cover.
Kura Oncology Inc (KURA) estimates and forecasts
Statistics show that Kura Oncology Inc has underperformed its competitors in share price, compared to the industry in which it operates. Kura Oncology Inc (KURA) shares have gone up 125.44% during the last six months, with a year-to-date growth rate less than the industry average at -12.98% against 13.40. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -10.00% this quarter and then drop -5.70% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -3.94%. While earnings are projected to return -10.26% in 2024, the next five years will return 19.93% per annum.
KURA Dividends
Kura Oncology Inc is due to release its next quarterly earnings between May 08 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kura Oncology Inc (NASDAQ:KURA)’s Major holders
Kura Oncology Inc insiders own 1.75% of total outstanding shares while institutional holders control 105.53%, with the float percentage being 107.40%. Suvretta Capital Management, LLC is the largest shareholder of the company, while 210 institutions own stock in it. As of Jun 29, 2023, the company held over 7.03 million shares (or 9.47% of all shares), a total value of $74.36 million in shares.
The next largest institutional holding, with 6.73 million shares, is of BVF Inc.’s that is approximately 9.07% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $71.21 million.
Also, the Mutual Funds coming in first place with the largest holdings of Kura Oncology Inc (KURA) shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 2.2 million shares. This amounts to just over 2.96 percent of the company’s overall shares, with a $23.23 million market value. The same data shows that the other fund manager holds slightly less at 1.67 million, or about 2.24% of the stock, which is worth about $16.54 million.
